Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...
A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some ...
Denver, Colo. - Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient ...
The expert in hematology/oncology discussed the results of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors. We ...
For 177Lu-PRRT, the mean number of cycles administered was 5.3 ± 2.5; for 90Y-PRRT, the mean number of cycles administered was 5.5 ± 2.6. Median overall survival was 79 months, but 32 percent of the ...
Association between duration of somatostatin analogs (SSAs) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument. This is an ASCO Meeting ...
A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC) No significant financial relationships to disclose. This is ...
"Personalized PRRT improves radiation delivery to neuroendocrine tumors." ScienceDaily. www.sciencedaily.com / releases / 2017 / 06 / 170612153541.htm (accessed September 28, 2026).
Neuroendocrine cancer can be exceedingly difficult to manage and can be unlikely to be cured. A research team from the Society of Nuclear Medicine has intended to slow down the progression of these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results